Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$18.83
-0.43-2.23%
At close: -
$18.83
0.000.00%
After Hours: Jun 13, 4:00 PM EDT
Comments
Loading...
Apellis Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:APLS | Benzinga
Apellis Pharmaceuticals Inc has a consensus price target of $43.35 based on the ratings of 21 analysts. The high is $106 issued by Raymond James on January 11, 2024. The low is $18 issued by RBC Capital on May 8, 2025. The 3 most-recent analyst ratings were released by Wells Fargo, Citigroup, and Mizuho on June 2, 2025, May 22, 2025, and May 14, 2025, respectively. With an average price target of $30 between Wells Fargo, Citigroup, and Mizuho, there's an implied 59.32% upside for Apellis Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wells Fargo
Citigroup
Mizuho
Raymond James
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Apellis Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/02/2025 | Buy Now | 54.01% | Wells Fargo | Derek Archila61% | $26 → $29 | Maintains | Equal-Weight | Get Alert |
| 05/22/2025 | Buy Now | 117.74% | Citigroup | Yigal Nochomovitz54% | $49 → $41 | Maintains | Buy | Get Alert |
| 05/14/2025 | Buy Now | 6.21% | Mizuho | Graig Suvannavejh52% | $30 → $20 | Maintains | Neutral | Get Alert |
| 05/09/2025 | Buy Now | 176.16% | Raymond James | Ryan Deschner76% | $75 → $52 | Downgrade | Strong Buy → Outperform | Get Alert |
| 05/09/2025 | Buy Now | 22.15% | B of A Securities | Tazeen Ahmad56% | $41 → $23 | Downgrade | Buy → Neutral | Get Alert |
| 05/08/2025 | Buy Now | -4.41% | RBC Capital | Luca Issi46% | $21 → $18 | Maintains | Sector Perform | Get Alert |
| 05/08/2025 | Buy Now | 6.21% | Scotiabank | Greg Harrison48% | $28 → $20 | Maintains | Sector Perform | Get Alert |
| 05/08/2025 | Buy Now | 38.08% | Wells Fargo | Derek Archila61% | $30 → $26 | Maintains | Equal-Weight | Get Alert |
| 05/08/2025 | Buy Now | 149.6% | Baird | Colleen Kusy36% | $55 → $47 | Maintains | Outperform | Get Alert |
| 05/07/2025 | Buy Now | 54.01% | Needham | Joseph Stringer62% | $40 → $29 | Maintains | Buy | Get Alert |
| 04/29/2025 | Buy Now | 133.67% | Cantor Fitzgerald | Eliana Merle49% | → $44 | Initiates | → Overweight | Get Alert |
| 04/21/2025 | Buy Now | 11.52% | RBC Capital | Luca Issi46% | $24 → $21 | Maintains | Sector Perform | Get Alert |
| 04/02/2025 | Buy Now | 64.63% | Scotiabank | Greg Harrison48% | $30 → $31 | Maintains | Sector Perform | Get Alert |
| 03/04/2025 | Buy Now | 186.78% | JP Morgan | Anupam Rama60% | $50 → $54 | Maintains | Overweight | Get Alert |
| 03/03/2025 | Buy Now | 32.77% | RBC Capital | Luca Issi46% | $26 → $25 | Maintains | Sector Perform | Get Alert |
| 03/03/2025 | Buy Now | 69.94% | Goldman Sachs | Salveen Richter52% | $36 → $32 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 54.01% | Wedbush | Laura Chico51% | $30 → $29 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 202.71% | HC Wainwright & Co. | Douglas Tsao53% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 202.71% | HC Wainwright & Co. | Douglas Tsao53% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | 38.08% | RBC Capital | Luca Issi46% | $26 → $26 | Maintains | Sector Perform | Get Alert |
| 01/21/2025 | Buy Now | 38.08% | RBC Capital | Luca Issi46% | $26 → $26 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 01/14/2025 | Buy Now | 202.71% | HC Wainwright & Co. | Douglas Tsao53% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 12/17/2024 | Buy Now | 91.18% | Goldman Sachs | Salveen Richter52% | → $36 | Downgrade | Buy → Neutral | Get Alert |
| 11/21/2024 | Buy Now | 64.63% | Morgan Stanley | Judah Frommer65% | → $31 | Initiates | → Equal-Weight | Get Alert |
| 11/07/2024 | Buy Now | 192.09% | Baird | Colleen Kusy36% | $92 → $55 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | 170.84% | Citigroup | Yigal Nochomovitz54% | $63 → $51 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 91.18% | Goldman Sachs | Salveen Richter52% | $71 → $36 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 27.46% | RBC Capital | Luca Issi46% | $25 → $24 | Maintains | Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | 59.32% | Scotiabank | Greg Harrison48% | $35 → $30 | Maintains | Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | 59.32% | Wells Fargo | Derek Archila61% | $43 → $30 | Maintains | Equal-Weight | Get Alert |
| 11/06/2024 | Buy Now | 112.43% | Oppenheimer | Justin Kim38% | $65 → $40 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | 69.94% | Piper Sandler | Biren Amin41% | $40 → $32 | Maintains | Neutral | Get Alert |
| 11/06/2024 | Buy Now | 202.71% | HC Wainwright & Co. | Douglas Tsao53% | $83 → $57 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 149.6% | B of A Securities | Tazeen Ahmad56% | $61 → $47 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 218.64% | Needham | Joseph Stringer62% | $85 → $60 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | 32.77% | RBC Capital | Luca Issi46% | $25 → $25 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 10/24/2024 | Buy Now | 101.81% | Mizuho | Graig Suvannavejh52% | $39 → $38 | Maintains | Neutral | Get Alert |
| 10/16/2024 | Buy Now | 85.87% | Scotiabank | Greg Harrison48% | → $35 | Initiates | → Sector Perform | Get Alert |
| 10/16/2024 | Buy Now | — | William Blair | Lachlan Brown38% | — | Initiates | → Outperform | Get Alert |
| 09/24/2024 | Buy Now | 128.36% | Wells Fargo | Derek Archila61% | $47 → $43 | Maintains | Equal-Weight | Get Alert |
| 09/23/2024 | Buy Now | 388.58% | Baird | Colleen Kusy36% | $96 → $92 | Maintains | Outperform | Get Alert |
| 09/20/2024 | Buy Now | 107.12% | Mizuho | Graig Suvannavejh52% | $42 → $39 | Maintains | Neutral | Get Alert |
| 09/20/2024 | Buy Now | 351.41% | Needham | Joseph Stringer62% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2024 | Buy Now | 202.71% | JP Morgan | Anupam Rama60% | $64 → $57 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 239.88% | JP Morgan | Anupam Rama60% | $72 → $64 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | 340.79% | UBS | Eliana Merle49% | $85 → $83 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | 117.74% | Wedbush | Laura Chico51% | $38 → $41 | Maintains | Neutral | Get Alert |
| 08/09/2024 | Buy Now | 292.99% | Goldman Sachs | Salveen Richter52% | $66 → $74 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | 409.82% | Baird | Colleen Kusy36% | $86 → $96 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | 351.41% | Needham | Joseph Stringer62% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2024 | Buy Now | 340.79% | HC Wainwright & Co. | Douglas Tsao53% | $92 → $83 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 250.5% | Goldman Sachs | Salveen Richter52% | $77 → $66 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 351.41% | Needham | Joseph Stringer62% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2024 | Buy Now | 324.85% | Jefferies | Akash Tewari42% | $80 → $80 | Maintains | Buy | Get Alert |
| 07/26/2024 | Buy Now | 356.72% | Baird | Colleen Kusy36% | $100 → $86 | Maintains | Outperform | Get Alert |
| 07/23/2024 | Buy Now | 431.07% | Baird | Colleen Kusy36% | $100 → $100 | Maintains | Outperform | Get Alert |
| 07/17/2024 | Buy Now | 308.92% | Goldman Sachs | Salveen Richter52% | $90 → $77 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 431.07% | Baird | Colleen Kusy36% | $100 → $100 | Maintains | Outperform | Get Alert |
| 05/31/2024 | Buy Now | 144.29% | Piper Sandler | Biren Amin41% | → $46 | Initiates | → Neutral | Get Alert |
| 05/28/2024 | Buy Now | 388.58% | HC Wainwright & Co. | Douglas Tsao53% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | 154.91% | Wells Fargo | Derek Archila61% | $57 → $48 | Maintains | Equal-Weight | Get Alert |
| 05/08/2024 | Buy Now | 351.41% | Needham | Joseph Stringer62% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 218.64% | Citigroup | Yigal Nochomovitz54% | $67 → $60 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 388.58% | HC Wainwright & Co. | Douglas Tsao53% | → $92 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 351.41% | UBS | Eliana Merle49% | $89 → $85 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | 176.16% | Mizuho | Graig Suvannavejh52% | $60 → $52 | Maintains | Neutral | Get Alert |
| 04/26/2024 | Buy Now | 388.58% | HC Wainwright & Co. | Douglas Tsao53% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 351.41% | Needham | Joseph Stringer62% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | 202.71% | Wedbush | Laura Chico51% | $67 → $57 | Maintains | Neutral | Get Alert |
| 04/15/2024 | Buy Now | 388.58% | HC Wainwright & Co. | Douglas Tsao53% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 351.41% | Needham | Joseph Stringer62% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 218.64% | Mizuho | Graig Suvannavejh52% | $60 → $60 | Maintains | Neutral | Get Alert |
| 03/06/2024 | Buy Now | 319.54% | JP Morgan | Anupam Rama60% | $78 → $79 | Maintains | Overweight | Get Alert |
| 03/04/2024 | Buy Now | 372.65% | UBS | Eliana Merle49% | $87 → $89 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 388.58% | HC Wainwright & Co. | Douglas Tsao53% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 255.82% | Wedbush | Laura Chico51% | $60 → $67 | Maintains | Neutral | Get Alert |
| 02/16/2024 | Buy Now | 218.64% | Mizuho | Graig Suvannavejh52% | $49 → $60 | Maintains | Neutral | Get Alert |
| 02/06/2024 | Buy Now | 330.16% | Baird | Colleen Kusy36% | → $81 | Reiterates | Outperform → Outperform | Get Alert |
| 02/05/2024 | Buy Now | 324.85% | Jefferies | Akash Tewari42% | $68 → $80 | Upgrade | Hold → Buy | Get Alert |
| 01/30/2024 | Buy Now | 319.54% | Oppenheimer | Justin Kim38% | $75 → $79 | Maintains | Outperform | Get Alert |
| 01/24/2024 | Buy Now | 298.3% | Needham | Joseph Stringer62% | $70 → $75 | Maintains | Buy | Get Alert |
| 01/17/2024 | Buy Now | 330.16% | Baird | Colleen Kusy36% | $71 → $81 | Maintains | Outperform | Get Alert |
| 01/17/2024 | Buy Now | 388.58% | HC Wainwright & Co. | Douglas Tsao53% | $82 → $92 | Maintains | Buy | Get Alert |
| 01/12/2024 | Buy Now | 218.64% | Wedbush | Laura Chico51% | $39 → $60 | Maintains | Neutral | Get Alert |
| 01/11/2024 | Buy Now | 462.93% | Raymond James | Steven Seedhouse58% | $67 → $106 | Maintains | Strong Buy | Get Alert |
| 01/09/2024 | Buy Now | 377.96% | Goldman Sachs | Salveen Richter52% | $65 → $90 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | 255.82% | Citigroup | Yigal Nochomovitz54% | $70 → $67 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | 298.3% | Oppenheimer | Justin Kim38% | $88 → $75 | Maintains | Outperform | Get Alert |
| 12/15/2023 | Buy Now | 255.82% | Raymond James | Steven Seedhouse58% | $93 → $67 | Maintains | Strong Buy | Get Alert |
| 12/14/2023 | Buy Now | 197.4% | Needham | Joseph Stringer62% | $63 → $56 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 186.78% | Wells Fargo | Derek Archila61% | $67 → $54 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/05/2023 | Buy Now | 351.41% | B of A Securities | Tazeen Ahmad56% | $52 → $85 | Upgrade | Neutral → Buy | Get Alert |
| 11/09/2023 | Buy Now | 292.99% | Goldman Sachs | Salveen Richter52% | → $74 | Initiates | → Buy | Get Alert |
| 11/02/2023 | Buy Now | 123.05% | Mizuho | Graig Suvannavejh52% | → $42 | Initiates | → Neutral | Get Alert |
| 11/02/2023 | Buy Now | 393.89% | Raymond James | Steven Seedhouse58% | $92 → $93 | Maintains | Strong Buy | Get Alert |
| 11/01/2023 | Buy Now | 234.57% | Needham | Joseph Stringer62% | $60 → $63 | Maintains | Buy | Get Alert |
| 10/12/2023 | Buy Now | 144.29% | B of A Securities | Tazeen Ahmad56% | $44 → $46 | Maintains | Neutral | Get Alert |
| 10/06/2023 | Buy Now | 271.75% | Citigroup | Yigal Nochomovitz54% | $54 → $70 | Maintains | Buy | Get Alert |
| 10/06/2023 | Buy Now | 330.16% | JP Morgan | Anupam Rama60% | $60 → $81 | Upgrade | Neutral → Overweight | Get Alert |
| 10/06/2023 | Buy Now | 388.58% | Raymond James | Steven Seedhouse58% | $89 → $92 | Maintains | Strong Buy | Get Alert |
FAQ
What is the target price for Apellis Pharmaceuticals (APLS) stock?
The latest price target for Apellis Pharmaceuticals (NASDAQ:APLS) was reported by Wells Fargo on June 2, 2025. The analyst firm set a price target for $29.00 expecting APLS to rise to within 12 months (a possible 54.01% upside). 58 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Apellis Pharmaceuticals (APLS)?
The latest analyst rating for Apellis Pharmaceuticals (NASDAQ:APLS) was provided by Wells Fargo, and Apellis Pharmaceuticals maintained their equal-weight rating.
When was the last upgrade for Apellis Pharmaceuticals (APLS)?
The last upgrade for Apellis Pharmaceuticals Inc happened on February 5, 2024 when Jefferies raised their price target to $80. Jefferies previously had a hold for Apellis Pharmaceuticals Inc.
When was the last downgrade for Apellis Pharmaceuticals (APLS)?
The last downgrade for Apellis Pharmaceuticals Inc happened on May 9, 2025 when Raymond James changed their price target from $75 to $52 for Apellis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Apellis Pharmaceuticals (APLS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apellis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apellis Pharmaceuticals was filed on June 2, 2025 so you should expect the next rating to be made available sometime around June 2, 2026.
Is the Analyst Rating Apellis Pharmaceuticals (APLS) correct?
While ratings are subjective and will change, the latest Apellis Pharmaceuticals (APLS) rating was a maintained with a price target of $26.00 to $29.00. The current price Apellis Pharmaceuticals (APLS) is trading at is $18.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
